| Schedule of segment and corporate information |
Segment and corporate information in € K | | | | | | | | | | | | | | | | | Care | | Value- | | Care | | Total | | Inter-segment | | | | | | | Delivery | | Based Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Three months ended September 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,211,730 | | 7,939 | | — | | 3,219,669 | | — | | — | | 3,219,669 | Revenue from healthcare products(1) | | 61,511 | | — | | 1,015,683 | | 1,077,194 | | — | | — | | 1,077,194 | Revenue from contracts with customers(1) | | 3,273,241 | | 7,939 | | 1,015,683 | | 4,296,863 | | — | | — | | 4,296,863 | Revenue from insurance contracts(1) | | — | | 567,578 | | — | | 567,578 | | — | | — | | 567,578 | Revenue from lease contracts(1) | | — | | — | | 20,409 | | 20,409 | | — | | — | | 20,409 | Revenue from external customers | | 3,273,241 | | 575,517 | | 1,036,092 | | 4,884,850 | | — | | — | | 4,884,850 | Inter-segment revenue | | 128,465 | | — | | 324,568 | | 453,033 | | (453,033) | | — | | — | Revenue | | 3,401,706 | | 575,517 | | 1,360,660 | | 5,337,883 | | (453,033) | | — | | 4,884,850 | Costs of revenue | | (2,564,750) | | (579,371) | | (942,765) | | (4,086,886) | | 448,587 | | (4,333) | | (3,642,632) | Research and development | | — | | — | | (37,954) | | (37,954) | | — | | 206 | | (37,748) | Operating income (loss) | | 419,474 | | (21,960) | | 86,652 | | 484,166 | | (3,454) | | (4,207) | | 476,505 | Interest | | | | | | | | | | | | | | (73,937) | Income before income taxes | | | | | | | | | | | | | | 402,568 | Depreciation and amortization | | (235,080) | | (1,354) | | (115,569) | | (352,003) | | 10,358 | | (16,569) | | (358,214) | Impairment loss | | (257) | | 21 | | 1,177 | | 941 | | — | | 16 | | 957 | Income (loss) from equity method investees | | 46,672 | | — | | — | | 46,672 | | — | | — | | 46,672 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 143,797 | | 117 | | 131,338 | | 275,252 | | (10,563) | | 14,763 | | 279,452 | | | | | | | | | | | | | | | | Three months ended September 30, 2024 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 3,291,969 | | 659 | | — | | 3,292,628 | | — | | — | | 3,292,628 | Revenue from healthcare products(1) | | 47,864 | | — | | 974,018 | | 1,021,882 | | — | | — | | 1,021,882 | Revenue from contracts with customers(1) | | 3,339,833 | | 659 | | 974,018 | | 4,314,510 | | — | | — | | 4,314,510 | Revenue from insurance contracts(1) | | — | | 429,946 | | — | | 429,946 | | — | | — | | 429,946 | Revenue from lease contracts(1) | | — | | — | | 15,706 | | 15,706 | | — | | — | | 15,706 | Revenue from external customers | | 3,339,833 | | 430,605 | | 989,724 | | 4,760,162 | | — | | — | | 4,760,162 | Inter-segment revenue | | 131,028 | | — | | 369,683 | | 500,711 | | (500,711) | | — | | — | Revenue | | 3,470,861 | | 430,605 | | 1,359,407 | | 5,260,873 | | (500,711) | | — | | 4,760,162 | Costs of revenue | | (2,695,842) | | (449,134) | | (965,043) | | (4,110,019) | | 495,918 | | 23 | | (3,614,078) | Research and development | | 41 | | — | | (40,018) | | (39,977) | | — | | (70) | | (40,047) | Operating income (loss) | | 456,012 | | (36,565) | | 60,802 | | 480,249 | | (4,205) | | (13,348) | | 462,696 | Interest | | | | | | | | | | | | | | (82,170) | Income before income taxes | | | | | | | | | | | | | | 380,526 | Depreciation and amortization | | (253,222) | | (1,082) | | (111,015) | | (365,319) | | 10,787 | | (17,561) | | (372,093) | Impairment loss | | 7,712 | | — | | (1,413) | | 6,299 | | — | | — | | 6,299 | Income (loss) from equity method investees | | 41,248 | | — | | — | | 41,248 | | — | | — | | 41,248 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 215,899 | | 97 | | 118,266 | | 334,262 | | (12,063) | | 9,133 | | 331,332 |
(1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
Segment and corporate information (continued) in € K | | | | | | | | | | | | | | | | | Care | | Value- | | Care | | Total | | Inter-segment | | | | | | | Delivery | | Based Care | | Enablement | | Segment | | eliminations | | Corporate | | Total | Nine months ended September 30, 2025 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 9,669,848 | | 51,486 | | — | | 9,721,334 | | — | | — | | 9,721,334 | Revenue from healthcare products(1) | | 193,944 | | — | | 3,020,787 | | 3,214,731 | | — | | — | | 3,214,731 | Revenue from contracts with customers(1) | | 9,863,792 | | 51,486 | | 3,020,787 | | 12,936,065 | | — | | — | | 12,936,065 | Revenue from insurance contracts(1) | | — | | 1,559,217 | | — | | 1,559,217 | | — | | — | | 1,559,217 | Revenue from lease contracts(1) | | — | | — | | 62,735 | | 62,735 | | — | | — | | 62,735 | Revenue from external customers | | 9,863,792 | | 1,610,703 | | 3,083,522 | | 14,558,017 | | — | | — | | 14,558,017 | Inter-segment revenue | | 365,425 | | — | | 991,913 | | 1,357,338 | | (1,357,338) | | — | | — | Revenue | | 10,229,217 | | 1,610,703 | | 4,075,435 | | 15,915,355 | | (1,357,338) | | — | | 14,558,017 | Costs of revenue | | (7,907,680) | | (1,558,685) | | (2,788,045) | | (12,254,410) | | 1,339,193 | | (2,243) | | (10,917,460) | Research and development | | — | | — | | (119,552) | | (119,552) | | — | | 206 | | (119,346) | Operating income (loss) | | 1,085,873 | | (27,553) | | 269,976 | | 1,328,296 | | (17,153) | | (77,965) | | 1,233,178 | Interest | | | | | | | | | | | | | | (229,403) | Income before income taxes | | | | | | | | | | | | | | 1,003,775 | Depreciation and amortization | | (739,402) | | (4,030) | | (339,443) | | (1,082,875) | | 30,600 | | (50,567) | | (1,102,842) | Impairment loss | | (17,336) | | (2,171) | | (4,522) | | (24,029) | | — | | 16 | | (24,013) | Income (loss) from equity method investees | | 139,680 | | — | | — | | 139,680 | | — | | — | | 139,680 | Total assets(1) | | 40,572,794 | | 584,495 | | 14,377,779 | | 55,535,068 | | (35,992,145) | | 11,344,082 | | 30,887,005 | thereof investment in equity method investees(1) | | 751,181 | | — | | — | | 751,181 | | — | | — | | 751,181 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 531,282 | | 315 | | 357,161 | | 888,758 | | (31,342) | | 26,738 | | 884,154 | | | | | | | | | | | | | | | | Nine months ended September 30, 2024 | | | | | | | | | | | | | | | Revenue from healthcare services(1) | | 9,924,270 | | 62,709 | | — | | 9,986,979 | | — | | — | | 9,986,979 | Revenue from healthcare products(1) | | 136,916 | | — | | 2,863,733 | | 3,000,649 | | — | | — | | 3,000,649 | Revenue from contracts with customers(1) | | 10,061,186 | | 62,709 | | 2,863,733 | | 12,987,628 | | — | | — | | 12,987,628 | Revenue from insurance contracts(1) | | — | | 1,205,997 | | — | | 1,205,997 | | — | | — | | 1,205,997 | Revenue from lease contracts(1) | | — | | — | | 57,497 | | 57,497 | | — | | — | | 57,497 | Revenue from external customers | | 10,061,186 | | 1,268,706 | | 2,921,230 | | 14,251,122 | | — | | — | | 14,251,122 | Inter-segment revenue | | 371,336 | | — | | 1,098,606 | | 1,469,942 | | (1,469,942) | | — | | — | Revenue | | 10,432,522 | | 1,268,706 | | 4,019,836 | | 15,721,064 | | (1,469,942) | | — | | 14,251,122 | Costs of revenue | | (8,159,146) | | (1,221,716) | | (2,833,270) | | (12,214,132) | | 1,454,132 | | (4,898) | | (10,764,898) | Research and development | | 19 | | — | | (133,382) | | (133,363) | | — | | (70) | | (133,433) | Operating income (loss) | | 958,104 | | (21,325) | | 196,296 | | 1,133,075 | | (8,680) | | 9,103 | | 1,133,498 | Interest | | | | | | | | | | | | | | (255,688) | Income before income taxes | | | | | | | | | | | | | | 877,810 | Depreciation and amortization | | (778,222) | | (3,336) | | (340,736) | | (1,122,294) | | 32,286 | | (53,582) | | (1,143,590) | Impairment loss | | (104,537) | | — | | (17,129) | | (121,666) | | — | | — | | (121,666) | Income (loss) from equity method investees | | 102,730 | | — | | — | | 102,730 | | — | | — | | 102,730 | Total assets(1) | | 42,680,707 | | 616,068 | | 15,501,825 | | 58,798,600 | | (37,315,733) | | 11,027,934 | | 32,510,801 | thereof investment in equity method investees(1) | | 690,794 | | — | | — | | 690,794 | | — | | — | | 690,794 | Additions of property, plant and equipment, intangible assets and right-of-use assets(1) | | 621,880 | | 451 | | 298,903 | | 921,234 | | (39,512) | | 35,260 | | 916,982 |
| (1) | These line items are included to comply with requirements under IFRS 8 and IFRS 15 or are provided on a voluntary basis, but not included in the information regularly reviewed by the chief operating decision maker. |
|